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Hypothesis: can the abscopal effect explain the impact of
adjuvant radiotherapy on breast cancer mortality?
Ismail Jatoi 1, John R. Benson2 and Ian Kunkler3
Radiotherapy is an integral component of loco-regional therapy for breast cancer. Randomized controlled trials indicate that
increasing the extent of extirpative surgery primarily reduces the risk of local recurrences, while the addition of radiotherapy to
surgery can also reduce the risk of distant recurrences, thereby lowering breast cancer-speciﬁc mortality. This may suggest an
“abscopal” effect beyond the immediate zone of loco-regional irradiation that favorably perturbs the natural history of distant
micrometastases. Immunological phenomena such as “immunogenic cell death” provide a plausible mechanistic link between the
local and systemic effects of radiation. Radiotherapy treatment can stimulate both pro-immunogenic and immunosuppressive
pathways with a potential net beneﬁcial effect on anti-tumor immune activity. Upregulation of programmed cell death ligand (PD-
L1) by radiotherapy is an immunosuppressive pathway that could be approached with anti-PD-L1 therapy with potential further
improvement in survival. The world overview of randomized trials indicates that the breast cancer mortality reduction from
adjuvant radiotherapy is delayed relative to that of adjuvant systemic treatments, and similar delays in the separation of survival
curves are evident in the majority of randomized immunotherapy trials demonstrating treatment efﬁcacy. In this article, we
hypothesize that an abscopal effect may explain the beneﬁt of radiotherapy in reducing breast cancer mortality, and that It might
be possible to harness and augment this effect with systemic agents to reduce the risk of late recurrences.
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INTRODUCTION
Surgery and radiotherapy are two forms of loco-regional therapy
that effectively reduce the risk of local recurrence in women with
primary breast cancer.1 However, in contrast to surgical interven-
tions, randomized trials have shown that addition of radiotherapy
to surgery not only improves loco-regional control but can also
reduce the risk of distant recurrence and death.2–7 Adjuvant
chemotherapy seems to act synergistically to enhance the
beneﬁcial effects of radiotherapy on breast cancer mortality.8
Moreover, the separation of survival curves in randomized trials of
adjuvant radiotherapy (i.e., radiotherapy versus no radiotherapy) is
delayed when compared to trials of adjuvant systemic therapy
(i.e., adjuvant systemic therapy versus no systemic therapy or
comparisons of different adjuvant systemic therapy regimens).9–11
An explanation for the beneﬁcial effects of radiotherapy on
overall survival remains obscure. It has been postulated that local
failure is a source for secondary dissemination of disease.12 Local
failure predicts for worse survival in breast cancer patients when
compared to those without locally recurrent disease after either
breast-conserving surgery (BCS) or mastectomy. Thus, amongst a
cohort of more than 2000 women treated with BCS and
postoperative irradiation of the breast, patients with local failure
had poorer 10 year survival than those maintaining local control
(55% versus 75%, respectively; P < .001).13 For those patients with
local recurrence, the peak time for development of disseminated
disease was 5–6 years post diagnosis, whereas for patients without
local recurrence (and a lower incidence of distant metastases), the
corresponding time interval was only 2 years. These observations
are consistent with metastatic spread from local recurrence.
Nonetheless, these data do not establish a direct cause–effect
relationship with several key prognostic factors being predictive
for both local recurrence and survival. If a cause–effect relation-
ship exists between local recurrence and survival, then a more
modest increment in survival from postoperative radiotherapy
after BCS compared to mastectomy might be attributable to the
overall greater likelihood of distant recurrence secondary to chest
wall recurrences after mastectomy than in- breast recurrence after
BCS.
As an alternative explanation, we hypothesize in this article that
breast cancer radiotherapy may have an “abscopal effect” giving
rise to the beneﬁcial effect of adjuvant radiotherapy on overall
survival.5,9 We consider what current evidence supports this
disruptive hypothesis, what challenges it, and what additional
evidence would be needed to conﬁrm it. Finally, recent advances
in immunotherapy provide an opportunity to harness any
abscopal effects by combining radiotherapy with immunomodu-
lators and immune checkpoint blockade to yield clinically mean-
ingful gains in survival outcomes.
BIOLOGICAL CONSIDERATIONS
The term “abscopal effect” was coined by R. H. Mole in 1953 as “an
action at a distance from the irradiated tissue volume but within
the same organism”, and alludes to radiotherapy effects at sites
distant from the primary zone of irradiation (Fig. 1).14 Also referred
to as the “distant bystander effect”, this implies that radiotherapy
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not only has localized action on target tissues but also out-of-ﬁeld
systemic anti-tumor effects.15
The linking of abscopal effects to the immune system was ﬁrst
proposed in 2004, with the observation that this effect could not
occur in T cell-deﬁcient mice.16 In some cases, radiotherapy may
activate host immune mechanisms and immunize a patient
against cancer by essentially changing the tumor into an in situ
vaccine. Localized radiation may also trigger systemic immuno-
modulatory antitumor effects, which have been demonstrated for
other tumors such as melanoma, renal cancer, and hepatocellular
carcinoma.17 Moreover, a combination of radiotherapy with
granulocyte-macrophage colony stimulating factor can generate
an abscopal response amongst patients with a variety of
metastatic solid tumors, including breast.18 The review by
Reynders and colleagues identiﬁed 23 case reports and 13
preclinical studies on the abscopal effect after radiotherapy
alone.17 Most of these effects were conﬁned to immunogenic
tumors such as melanoma and renal cell carcinoma for which a
combination of immunoadjuvants with radiotherapy improved
the abscopal response rates compared to radiation alone.19
Therapeutic strategies incorporating agents which speciﬁcally
enhance host immune function may render any abscopal effects
more prominent in less immunogenic tumors such as breast
cancer20).
There is accumulating preclinical evidence supporting the idea
that the clinical effectiveness of radiation involves interactions
between the stroma and the tumor cell.21 For instance, radio-
therapy may induce local cell death with subsequent release of
immunogenic factors, a process termed “immunogenic cell
death”.22 These immunogenic factors include calreticulin which
is translocated to the cell surface after immunogenic cell death
where processing by dendritic cells facilitates tumor antigen
presentation and stimulation of cytotoxic T lymphocytes.23,24 Thus
radiotherapy can mobilize host immune effector mechanisms
which involve both pro-immunogenic and immunosuppressive
effects. These might contribute to overall survival by an abscopal
effect which depends upon the overall balance of these opposing
inﬂuences and this in turn is determined by tissue context and
radiation dosage.25 Furthermore, in preclinical breast cancer
models, localized radiotherapy can directly stimulate release of
chemokines (e.g., CXCL10 and CXCL16) that modulate immuno-
logical response by mechanisms involving increased expression of
adhesion molecules such as E-selection and ICAM-1) in endothelial
cells.26
Emerging evidence from pre-clinical models suggests that local
radiation treatment can indirectly enhance systemic anti-tumor
immune activity.27,28 Tumor-induced immune suppression not
only promotes tumor growth and dissemination but also can
interfere with efﬁciency of radiation dosage.29 Ideally, radio-
therapy should promote immunostimulatory and minimize tumor-
induced immune suppressive effects thereby leading to a net
enhancement of T-cell mediated immune attack.22,30
One of the key immune checkpoint receptors is programmed
cell death-1, which limits the response of effector T cells when
bound to its programmed cell death ligands (PD-L1 and PD-L2).
Radiotherapy upregulates PD-L1 in tumor cells. This in turn
negatively regulates T-cell functioning and T-cell mediated anti-
tumor activity, resulting in a poorer prognosis.28,31 The immune
response of T-cells and intra-tumoral T-cell inﬁltration is poten-
tiated by pharmacological blockade of the PD-L1 and PD-1
pathways, and this can increase local tumor control in melanoma
and breast cancer mouse models which have been treated with a
Fig. 1 Ionizing radiation and the abscopal effect
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combination of radiotherapy and anti-PD-1 antibody.27,32 More-
over, radiotherapy combined with PD-L1 signaling blockade
improves not only local control but also long-term survival
compared with radiotherapy alone in tumors of syngeneic mice,
further emphasizing a synergistic interaction between irradiation
and anti-PD-L1 strategies.22,30 Likewise, this approach is supported
by experiments using immunocompetent mouse models whereby
blocking the PD-L1 pathway results in longer tumor growth delay
following irradiation.30 Consistent with these observations, deple-
tion of T-cells reduces the anti-tumor efﬁcacy of radiation therapy
which is partially compensated for by blockade of the PD-L1/PD-1
axis.32 Dual immune checkpoint blockade may be necessary to
prevent emergence of resistance from upregulation of other
checkpoint receptors.28
The concept of ‘radiation-induced equilibrium (RITE) has been
proposed by Weichselbaum and colleagues who have evaluated
the respective roles of intrinsic radiosensitivity and the immune
system.33 These authors have explored how innate and adaptive
immunity contribute to the processes of RITE and dormancy in
pre-clinical models of HER2 positive breast cancer and B16
melanoma, which display heterogeneous responses to radio-
therapy. Tumors that showed a variable response to radiation
(cases of non-responders, early relapse, stable disease and late
relapse) were excised and single cell suspensions derived from
tumors. These were then irradiated ex vivo (2.5 or 10 Gy) prior to
evaluation by clonogenic assays. Cells showed differential
sensitivity to radiotherapy in vivo but similar radiosensitivity
ex vivo. It was observed that areas of cell death were associated
with a plethora of CD8+cells in stable irradiated tumors while
regrowth of stable cancers was linked to a reduction in levels of
CD8+cells. Therefore, RITE may represent a balance between cell
death and cell regeneration which is principally mediated by CD8
+cells. Furthermore, a state of therapy-induced equilibrium exists
between division of tumor cells and killer cell activity by the host
immune system, and this in turn determines disease status.
CLINICAL IMPLICATIONS
If radiotherapy has an abscopal effect in breast cancer patients,
then why is it rarely witnessed from a clinical perspective? The
relative infrequency of abscopal effects in clinical practice could
be due to a number of factors. First, it is likely partly due to
negation of pro-immunogenic effects of radiotherapy by counter-
balancing immunosuppressive effects. Immune-based therapies
can take advantage of potentially synergistic interactions between
agents such as anti-PD-L1 and radiation-induced anti-tumor
immune effects.29,34 Moreover, these systemic interactions could
augment any abscopal effects and improve disease-speciﬁc
survival. Crucial clinical questions relate to the timing of
administration of anti-PD-L1 therapies and whether these should
be concurrent with irradiation to not only maximize any abscopal
effect but also harness any radiosensitizing effects of immu-
notherapy.27 Potential toxicity could ensue from simultaneous
treatments, although these do appear to be more efﬁcient in pre-
clinical studies than sequential approaches.
Another possibility, yet to be proven, is that the predominant
beneﬁt of the abscopal effect is critically dependent on tumor
burden. The maximal effect is perhaps on micrometastatic disease,
and this might explain the beneﬁcial effects of radiotherapy for
other solid tumors in combination with systemic therapy, which
may serve as the dominant partner in reducing the micrometastic
cell burden. This might explain why there is minimal evidence to
support our hypothesis in advanced breast cancer, with no clear
evidence that loco-regional radiotherapy has any impact on
distant metastases or survival outcomes in the setting of stage IV
disease; in these circumstances, any abscopal effect might be
overwhelmed.
To date, relatively little attention has been paid to any potential
abscopal effects following breast cancer radiotherapy, but there is
a growing body of evidence to support the existence of this
phenomenon. Immunological (i.e., abscopal) effects can be
delayed, and their potential occurrence should perhaps now be
considered when designing and analyzing breast cancer radio-
therapy trials.35 Longer follow-up of these trials might better
elucidate these potential effects.10,36
EVIDENCE FROM CLINICAL TRIALS
Over the past 50 years, numerous randomized trials have
compared various permutations of local therapy for breast cancer
with evident differences in outcomes between trials comparing
surgery alone versus those combined with radiotherapy. Rando-
mized comparisons of surgical extent, be this in relation to the
breast (breast-conserving surgery versus mastectomy), axilla
(axillary surgery versus no axillary surgery or more versus less
expansive axillary surgery), or the internal mammary nodes
(surgical extirpation versus no extirpation), have all consistently
shown that more extensive surgery reduces the risk of local
recurrence, but has no corresponding reductive effect on risk of
distant recurrence and mortality.37–40
In contrast to trials of surgical treatments, randomized trials
have shown that the addition of radiotherapy to surgery not only
reduces the risk of loco-regional recurrence, but can also
signiﬁcantly lower the risk of distant recurrence and death. Thus,
both the Danish and British Columbia trials randomized high-risk
breast cancer patients to modiﬁed radical mastectomy and
systemic therapy versus modiﬁed radical mastectomy and
systemic therapy with radiotherapy.2,3 The addition of radio-
therapy signiﬁcantly reduced the risk of distant recurrence and
mortality. Furthermore, a pooled analysis of published randomized
trials that compared radiotherapy versus no radiotherapy after
breast conserving surgery showed that omission of radiotherapy
was associated with a large increase in risk of ipsilateral breast
tumor recurrence, and an increase in mortality of 8.6% (95% CI=
0.3% to 17.5%).4 A similar meta-analysis undertaken by the Early
Breast cancer Trialists’ Collaborative Group (ECBCTCG) found that,
after breast conserving surgery, radiotherapy to the conserved
breast halved the rate at which the disease recurs and reduced the
breast cancer death rate by about a sixth.5 More recently, the
National Cancer Institute of Canada (NCIC) MA.20 and the
European Organization for Research and Treatment of Cancer
(EORTC) 22922-10925 randomized trials compared breast radio-
therapy alone versus breast radiotherapy with the addition of
radiotherapy to the nodal ﬁelds in patients with primary breast
cancer.6,7 Both of these trials conﬁrmed that extended nodal
irradiation reduced not only the risk of local-regional recurrence,
but also the risk of metastatic breast cancer–the latter being a
surrogate for overall survival. Thus, with longer follow-up of these
trials, it might be expected that addition of regional nodal
radiotherapy would eventually demonstrate a survival beneﬁt.
Results of the NCIC MA.20 and EORTC 22922-10925 trials are
particularly provocative as they demonstrate a reduction in risk of
distant recurrence from extended regional nodal radiotherapy,
despite lack of any such beneﬁt from more expansive surgical
extirpation of regional lymph nodes. Indeed, the American College
of Surgeons Oncology Group (ACOSOG) Z0011 trial which
randomized sentinel node-positive breast cancer patients to
sentinel node biopsy alone versus sentinel node biopsy followed
by surgical clearance of the axilla, found no survival beneﬁt for
patients with sentinel node-positive tumors undergoing surgical
clearance of the axilla.39 Moreover, amongst patients in the
surgical clearance group, 27.3% had additional metastasis in non-
sentinel lymph nodes, and yet leaving this residual disease behind
in the group receiving sentinel node biopsy only did not affect
outcomes. Thus, although both surgery and radiotherapy have
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traditionally been designated as “local therapies”, results of these
trials raise the possibility that breast radiotherapy may also have
systemic effects.
Adjuvant chest wall and breast irradiation improves overall
survival signiﬁcantly, whereas at present we only have evidence of
a modest impact of regional nodal irradiation on disease-free
survival but not overall survival in the NCIC MA-20 and EORTC
22922-10925 trials. This raises the possibility that the abscopal
effect may differ between local irradiation of the breast/chest wall
versus regional nodes. It is therefore not clear as to whether any
potential abscopal effects become apparent only after irradiation
of the primary tumor, after regional nodal irradiation as well, or
whether irradiation of the primary tumor and regional nodes
produce abscopal effects that are similar in magnitude.41
However, based on the available evidence from clinical trials, it
would seem reasonable to initially explore the abscopal effect in
the setting of chest wall and breast irradiation, where the overall
impact of adjuvant radiotherapy is greatest.
Another important consideration is whether the abscopal
response may differ according to tumor subtype. A recent analysis
of a large randomized trial assessing the effect of adjuvant
radiotherapy following breast-conserving surgery found that
tumor subtype was not predictive of response to radiotherapy.42
Thus, to date, there is no evidence that tumor subtype has an
inﬂuence on any potential abscopal effect.
The beneﬁts of radiotherapy on distant recurrence and death
are particularly evident in clinical trials whenever adjuvant
systemic chemotherapy is administered. In the aforementioned
randomized trials where an overall mortality beneﬁt was evident
following radiotherapy to either the breast or chest wall,
chemotherapy was offered as adjunctive treatment. Whelan and
colleagues tested a different hypothesis explaining why previous
meta-analyzes had failed to demonstrate any beneﬁcial effect of
radiation therapy on mortality.8 These authors hypothesized that
adjuvant systemic therapy was necessary for loco-regional therapy
per se to manifest any mortality effect.8 In a meta-analysis of
eighteen randomized trials where loco-regional radiotherapy was
administered after surgery and all patients were treated with
systemic therapy, irradiation after surgery was shown to
signiﬁcantly reduce overall mortality (Odds Ratio 0.83; 95% CI,
0.74 to 0.94).8 One might speculate that chemotherapy augments
innate anti-tumor immune mechanisms by inducing immuno-
genic cell death and may also disrupt tumor strategies used to
evade immune recognition.43 Alternatively, as discussed pre-
viously, adjuvant chemotherapy may lower the burden of
micrometastatic disease, thereby enabling an abscopal effect.
Thus, adjuvant chemotherapy may have an important role in
enhancing any immunomodulatory effects of radiotherapy that
can impact breast cancer mortality.
Although both systemic therapy and radiotherapy in the
adjuvant setting can reduce breast cancer mortality, meta-
analysis of randomized trials reveals that separation of survival
curves occurs at different time-points for each modality following
initial diagnosis and treatment.9–11,36 Thus the mortality beneﬁt
from adjuvant systemic therapy is evident within the ﬁrst three
years following breast cancer diagnosis and treatment, while gains
from adjuvant radiotherapy emerge distinctly later (i.e., beyond
three years). A delayed separation of survival curves has been
observed in the majority of randomized cancer immunotherapy
trials demonstrating treatment efﬁcacy, and would be consistent
with an abscopal response.35 Clinical trials that demonstrate a
delayed response deviate from the standard proportional hazards
model that is generally used in the design and analysis of cancer
clinical trials.10,36 Under the proportional hazards model, the
relative beneﬁts of treatment are assumed to be constant over
time, and delayed treatment effects might be overlooked with
short-term follow-up. Extended follow-up may therefore be
required to fully assess therapeutic efﬁcacy if immunological
(i.e., abscopal) effects are contributory to overall clinical outcomes.
The beneﬁts of breast cancer radiotherapy on distant recur-
rence and overall mortality are generally evident in more recent
trials discussed above. However, the AMAROS (After Mapping of
the Axilla: Radiotherapy or Surgery} is a notable exception. This
trial showed no differences in disease free survival and overall
survival between the axillary radiotherapy and axillary surgery
groups. Yet, the AMAROS trial was underpowered due to the small
number of events, and it is therefore difﬁcult to draw any
conclusion regarding potential effects of axillary radiotherapy.
Older trials have generally failed to demonstrate a beneﬁcial
effect of radiotherapy in reducing distant recurrences and death.
This might be due to infrequent or absent usage of adjuvant
chemotherapy in these older trials or to outmoded radiotherapy
techniques that yielded an excess of cardiac mortality. Thus, the
National Surgical Adjuvant Breast and Bowel Project (NSABP)-04
and Kings/Cambridge trials pre-dated the era of modern adjuvant
chemotherapy, and none of the patients were offered systemic
therapy.38,44 Both trials failed to demonstrate any survival beneﬁt
from nodal irradiation in terms of either distant recurrence or
mortality. In the NSABP-04 trial, 1079 clinically node-negative
patients were randomized to mastectomy plus axillary lymph
node dissection, versus mastectomy plus axillary radiotherapy,
versus mastectomy and observation of the axilla with treatment
intervention at relapse only.38 In the Kings/Cambridge trial,
patients were randomized to either mastectomy plus axillary
radiotherapy versus mastectomy and axillary observation.44 These
trials suggest that surgery and radiotherapy are equally effective
in reducing the risk of axillary recurrence (risk reduction
approximately from 20% down to 2%), with no beneﬁt of either
axillary surgery or radiotherapy in reducing overall mortality
(overall survival comparable for axillary dissection, axillary radio-
therapy and observation only).
Similarly, six randomized trials were initiated more than 30 years
ago comparing breast-conserving surgery (lumpectomy+radio-
therapy) versus mastectomy without radiotherapy, and failed to
demonstrate a beneﬁt of breast cancer radiotherapy in lowering
overall mortality (patients in both arms received axillary dissec-
tion).45 The largest of these breast conserving surgery trials was
the NSABP-06 trial, which randomized 1851 patients to one of
three arms: lumpectomy alone, lumpectomy combined with
breast radiotherapy, or mastectomy.37 There were no differences
in overall survival and no net mortality beneﬁt from addition of
radiotherapy despite a substantial effect on risk of local relapse.
Nonetheless, after twenty years of follow-up, there were fewer
deaths attributed to recurrent or contralateral breast cancer in the
lumpectomy and radiotherapy group (198 deaths) compared with
the lumpectomy alone group (242 deaths), but more non-breast
cancer deaths in the lumpectomy and radiotherapy group (85
deaths) when compared to the lumpectomy group (62 deaths).37
It is therefore possible that radiotherapy produced an excess in
non-breast cancer (i.e., cardiac) deaths amongst patients in these
older trials, thereby canceling out any beneﬁcial effects in terms of
lowering breast cancer mortality. Modern tangential radiotherapy
techniques avoid direct irradiation of the heart (incorporate ‘heart
spare’) and deliver a more effective dose using intensity
modulation to target the zone of the breast where risk of breast
cancer recurrence is greatest.46 Thus, in the modern era, any
reduction in breast cancer deaths attributable to radiotherapy can
translate to improvements in overall survival.
ADDITIONAL EVIDENCE REQUIRED
So what additional evidence might be needed to conﬁrm a
clinically relevant abscopal effect for adjuvant radiotherapy in
early breast cancer? The current state of knowledge derived from
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preclinical and clinical data is incomplete and inadequate to
conﬁdently declare or refute any abscopal effect.
Both clinical and experimental data suggest that any abscopal
effect occurs following adequate activation of an anti-tumor
response from local irradiation.16 This prompted the hypothesis
that combining immunotherapy with radiation could potentially
be synergistic and result in enhanced immune-mediated systemic
anti- tumor effects47
Clinically overt cancers have usually acquired resistance to
immune-mediated anti-tumor effects. Immunosuppressive effects
of tumors include a number of local and systemic processes such
as overexpression of T cell inhibitory signals, underexpression of
co-stimulatory signals and reducing presentation of antigens.48 A
principal focus of clinical and translational studies combining
immunotherapy with radiotherapy is enhancement of immunos-
timulatory signals while blocking inhibitory signals. Radiation in
combination with immunostimulatory molecules such as
Interleukin-2 (IL2), Toll-like receptor (TL-R) ligands and FMS-like
tyrosine-kinase 3 (Flt-3) ligand have been used pre-clinically to
engender the abscopal effect in mouse models of breast cancer. In
one study, breast cancer cells were implanted bilaterally into the
ﬂanks of mice, one side of which was then irradiated and Flt-3
administered.16 Tumor growth was inhibited on the irradiated but
not the un-irradiated side after RT alone. When both RT and Flt-3
were given, delayed growth was observed on both irradiated and
non-irradiated sides. TLRs augment presentation of antigen,
upregulating costimulatory molecules on dendritic cells and
stimulating the production of cytokines. The TLR7 ligand agonist
(imiquinod) has been combined with radiation in a mouse model
of skin metastases from breast cancer.49 Primary and secondary
sites were injected with breast cancer cells and tumor growth was
suppressed at both sites when imiquinod was applied topically to
the primary site alone (reduction of tumor volumes). This
inhibitory effect was enhanced if both primary and secondary
sites were treated with imiquimob but only the primary site
irradiated.
Clinical studies of radiation combined with checkpoint inhibitors
Immune checkpoints play a key role in modulating the
inﬂammatory response to infection. In the tumor microenviron-
ment, disrupted regulation of these immune checkpoints com-
promises host immune response to cancer. Cytotoxic T
lymphocyte-associated protein-4 (CTLA-4) and programmed cell
death-1 (PD-1) are two checkpoint inhibitors that have been
extensively evaluated. A number of clinical trials are in progress
evaluating a combination of CTLA4/PDI/PDL1 in inhibitors in
patients with metastatic breast cancer.50,51 In a phase 2 study of
metastatic triple negative breast cancer the PDL1 Inhibitor
pembrolizumab is being combined with radiation (5 × 6 Gy over
5–7 days) for patients with at least two measurable tumors.52 In a
study combining radiation with GM-CSF and local irradiation of
metastatic solid tumors (3.5 Gy × 10), 5 out of 14 breast cancer
patients had a demonstrable abscopal response.18 Clinical trials
combining radiation therapy and immune checkpoint blockade
have shown responses in up to 19% of breast cancer patients
(some of which are durable).20 Any abscopal response may be
inﬂuenced by the volume of the irradiated tumor. It has been
hypothesized that larger tumors may release larger amounts and
variety of neoantigens.53 The relative infrequency of abscopal
effects in response to combined radiation and immune check-
point inhibitors in breast cancer may partly be due to
immunosuppressive regulators within the tumor microenviron-
ment. These include transforming growth factor beta, regulatory
T cells and myeloid derived suppressor cells (MDSCs) which
collectively have an immunosuppressive role.
Counteracting these immunosuppressive regulators is being
explored in preclinical murine models. When a neutralizing
antibody to TGF beta was administered in combination with
radiation (5 daily doses of 6 Gy) to mice bearing breast tumor
xenografts, there was dendritic cell activation and a strong CD8
+response. Tumor growth was inhibited in both locally irradiated
tumors and distant metastases, although tumor progression
occurred after an initial response54
Caution is needed when extrapolating from evidence based on
different tumor models involving a variety of dose and fractiona-
tion regimens. The optimal dose, fraction size, and timing of
radiation in conjunction with immunomodulation to maximize an
abscopal response remains to be determined and a ‘one size ﬁts
all’ approach is unlikely to be applicable. In particular, it is unclear
whether a single low dose of radiation (e.g., 0.5–2.5 Gy) more
effectively suppresses tumor growth, compared with hypofractio-
nated doses of 6–8 Gy or even standard doses of 2 Gy which may
themselves be more efﬁcacious than a large single dose.20 It is
unusual for conventional fractionated doses of radiotherapy alone
to generate an abscopal response, implying that immunostimu-
latory properties of radiation are inadequate to counteract the
immunosuppressive microenviroment in most human tumors.55 A
meta-analysis of trials of adjuvant regional nodal irradiation has
shown improved disease-free, metastases-free and overall survival
in stage 1-111A breast cancer.56 However, on the basis of pre-
clinical studies on breast tumors, it seems unlikely that these
improved outcomes can be attributable to an abscopal effect of
radiotherapy alone on local treatment of nodal ‘oligometastases’.
Despite promising research, molecular mechanisms underlying
the abscopal effect remain incompletely understood and future
research efforts should focus on identifying the optimum
sequencing of immunotherapy in relation to local radiation
treatment. Insights into potential mechanisms for an abscopal
effect come from work with local radiotherapy combined with
immunotherapy in mice in which an irradiated tumor is converted
to an in situ vaccine. A key step in this process is induction of
interferon type-1 (IFN-1) which can recruit dendritic cells and
prime T-lymphocytes involved in cell-mediated immunity. Irradia-
tion of tumors produces double-stranded DNA fragments which
can migrate into the cytoplasm and activate a synthase enzyme
(cGAS) and its adapter protein STING, thus triggering IFN-1.57
Herrera and colleagues provide a useful framework to address
these clinical questions58 Three scenarios need to be considered:
1) Immune therapy added to standard hypofractionated radio-
therapy oligometastatic disease (aiming to take advantage of the
in situ vaccination effect of radiation); 2) Immunotherapy
combined with standard chemo-radiation (to enhance effect of
chemo-RT on local and systemic synergy of RT and immunomo-
dulation); 3) Radiation added to immunotherapy (aiming to
maximize the efﬁcacy of immunotherapy with radiation acting
as biological response modiﬁers). Useful guidelines on immune-
related response criteria are available.59 The extent to which
studies of the abscopal effect of radiotherapy in the metastatic
setting can be extrapolated to the adjuvant setting, in which the
primary tumor has been resected followed by systemic treatment,
remains unknown. However, advanced disease provides the
context for understanding mechanisms that might be relevant
to adjuvant postoperative radiotherapy (i.e., after mastectomy or
breast conserving surgery). The size of nodal deposits may be
critical in terms of an abscopal response, with larger tumors
generating more immunostimulatory neo-antigens but dispropor-
tionate enhancement of the immunosuppressive microenviron-
ment.53 Negating these immunosuppressive effects is important,
and a strategy of dual blockade may speciﬁcally stimulate the
immune system and negative immunosuppressive effects of
radiotherapy.
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Biomarkers of immune response
Responses to immune checkpoint blockade are variable and
unpredictable between and within any single tumor type. To
harness abscopal effects into clinically meaningful treatments,
biomarkers of immune response are needed. DNA damage and
repair signiﬁcantly inﬂuence interactions between tumors and the
immune system, with DNA repair being an important biomarker of
immune checkpoint blockade response.55 DNA repair deﬁciency
leads to a greater mutational load and quantity of neo-antigen
and levels of both correlate with response rates. However, a high
mutational load is not essential for generation of an immune
checkpoint blockade response. It is likely that a spectrum of
immunological effects is associated with various DNA repair
deﬁcient settings.55 A greater understanding is needed of the
impact of genomic instability which may be induced in non-
irradiated tissues via a bystander effect. Clinical validation of DNA
as a biomarker is necessary before use in clinical decision-making
for selection of patients likely to beneﬁt from combined radiation
and immunomodulation.
A recent meta-analysis of abscopal effects in preclinical models
(including breast cancer) estimates that a biologically effective
dose (BED) of 60 Gy has a 50% probability of inducing an abscopal
effect, although the relevance of these ﬁndings to breast cancer in
women is uncertain.60 Despite signiﬁcant heterogeneity in the
dose and fractionation regimens employed in the Oxford
overview, it should be noted that a meta-analysis of trials of
post-mastectomy radiotherapy used biologically equivalent doses.
Trials using a BED of 40–60 Gy with an appropriate target volume
were associated with a 6.4% absolute increase in survival up to 10
years (OR of death= 0.78; 95% CI 0.70–0.85; p < 0.001).61
However, whether there is a dose threshold for the abscopal
effect is uncertain. Moreover, we do not know if the standard dose
and fractionation regimes of adjuvant radiotherapy are optimal for
leveraging the abscopal effect, nor whether radiotherapy admi-
nistered before breast surgery might augment any abscopal
effects.62 We need biomarkers of an abscopal effect of radiation
which could be tested on clinical datasets of patients treated by
mastectomy or breast conserving therapy, and appropriate
systemic therapy randomized in clinical trials to postoperative
radiotherapy or no radiotherapy. To date, there are no published
molecular signatures of the abscopal effect in breast cancer or any
other solid tumor and no validated biomarkers of likely response
to combined radiotherapy and immunotherapy.63 Potential
immunological surrogates for immune response are under
investigation and include cytokine proﬁles, antibody titers
changes in peripheral blood immune cells, and tumor inﬁltrating
immune cell phenotypes. In addition, we need to know more
about the factors which modulate the balance between the
immune-activating and immunosuppressive signals induced by
radiation, and the targets which would allow radiation immunity
to be enhanced.64
If our hypothesis is validated by further data, the impact on
clinical practice could be transformational. We might in future be
able to identify at diagnosis subsets of patients whose breast
tumors have the capacity for an immune-mediated abscopal effect
from an optimal dose fractionation regime enacted and enhanced
by speciﬁc adjuvant systemic therapies. The purpose of radio-
therapy would shift from direct tumor cell kill to modulation of the
immune system consequent to increased neo-antigen exposure.
Out-of-target metastatic tumor foci would therefore be targeted
not only with conventional systemic therapies, but also these
distant bystander immune effects, thus increasing the chance of
eradicating distant disease foci.
CONCLUSION
Potential abscopal effects following radiotherapy should be
exploited to further lower breast cancer mortality. New immu-
notherapeutic agents such as checkpoint inhibitors and TLR
agonizts could be developed to enhance this abscopal effect and
thereby produce a more robust response. Moreover, use of dual
immune checkpoint blockade may help prevent adaptive immune
resistance and maintain the pro-immunogenic effects of local
radiotherapy.65 The potential synergism between chemotherapy
and breast cancer radiotherapy might be bolstered by future
development of similar (but less toxic) immunogenic modulators
to maximize the abscopal response. It should be noted that
systemic therapies have largely been effective in reducing the risk
of breast cancer recurrence and deaths during the initial three to
ﬁve years following diagnosis.10 With increasing numbers of long-
term breast cancer survivors, there is an urgent need to lower the
burden of delayed recurrences and deaths. Harnessing the
abscopal response within the context of a permissive host/tumor
environment may provide an opportunity to do so. A better
biological understanding of how abscopal effects are dependent
on factors such as radiation dose, fractionation, and timing will
help maximize the clinical impact and may serve to further lower
the global burden of breast cancer mortality. Current consensus is
that multidisciplinary collaboration will permit leverage of
abscopal effects which could transform the ﬁeld of radiation
oncology.19 This would apply to breast cancer, as well as other
solid tumors in which radiotherapy has a key role in curative
therapy. Further research will be needed to conﬁrm or refute this
hypothesis.
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